Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 135

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 135
---
 such country for such licensed product and (iii) the tenth anniversary of the first commercial sale of a licensed product in such country.

97

In addition, we are required to pay AbbVie up to $130.0 million in commercial and sales-based milestone payments, mid to high single-digit royalties on the licensed products or other payments due to Galapagos pursuant to the Galapagos License Agreement, to the extent such payments are triggered by our use of the licensed rights owned by Galapagos under the AbbVie License Agreement. As of September 30, 2024, none of such milestones under the AbbVie License Agreement and Galapagos License Agreement have been achieved. Components of Results of Operations Revenue To date, we have not generated any revenue. In the future, we may generate revenue from product sales from any approved product, which approval we do not expect to occur for at least the next several years, if ever, as well as collaboration or license agreements we may enter into with respect to our current or future product candidates. If our development efforts for our current or future product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue as we may never succeed in obtaining regulatory approval for any of our product candidates. If we fail to complete preclinical and clinical development of our current or future product candidates or fail to obtain regulatory approval for any that successfully complete clinical trials, our ability to generate future revenues, and our results of operations and financial position would be adversely affected. Operating Expenses Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses. Research and Development Expenses Research and development expenses consist primarily of costs associated with the preclinical and clinical development of our current and potential future product candidates. In particular, our research and development expenses include:

| • |     | personnel-related costs, including salaries, payroll tax, bonuses, benefits and stock-based compensation for employees 
 engaged in research and development functions;                                                                         |

| • |     | the costs to acquire in-process research and development with no alternative future 
 use acquired in an asset acquisition;                                               |

| • |     | external expenses, including expenses incurred under arrangements with third parties, such as contract research                  
 organizations (“CROs”), contract development and manufacturing organizations (“CDMOs”), consultants and our scientific advisors; |

| • |     | the cost of manufacturing our product candidates, including costs for laboratory supplies, research materials